8-K: Oramed Grants Scilex Option to Repurchase Warrants, Extends Note Maturity

Oramed Pharmaceuticals Inc. has entered into an agreement granting Scilex Holding Company an option to repurchase 6.5 million warrants for $27 million, which, if exercised, will extend the maturity of a $101.875 million promissory note.

Summary

• Oramed granted Scilex an option to repurchase 6,500,000 Penny Warrants (Subject Warrants) for an aggregate purchase price of $27,000,000.
• Scilex will pay Oramed $1,500,000 for this option in two equal installments of $750,000, due by August 8, 2025, and December 16, 2025.
• The warrant repurchase is structured in two tranches: 3,130,000 warrants for $13,000,000 by September 30, 2025, and 3,370,000 warrants for $14,000,000 by December 31, 2025.
• Successful completion of the warrant repurchase and option payments will extend the maturity date of Scilex's $101,875,000 Senior Secured Promissory Note (Tranche A Note) to March 31, 2026, and waive any make-whole payment upon prepayment.
• Oramed clarified that the exercise price of its 6,500,000 Penny Warrants remains $0.01 per share, correcting a previous Form 10-Q statement regarding the impact of Scilex's 1-for-35 reverse stock split.

Sentiment

Score: 7

Explanation: The filing indicates a positive development for Oramed as it provides a clear path to monetize its warrant holdings and secure the extension of a significant promissory note. The clarification of warrant terms is also favorable. However, the transaction's full benefit is contingent on Scilex's performance and adherence to payment schedules, introducing some residual risk.

Positives

• Potential to receive $28,500,000 in cash ($1.5M option fee + $27M repurchase price) for warrants.
• Extension of the $101,875,000 Tranche A Note maturity date to March 31, 2026, providing Scilex more time to repay.
• Waiver of any make-whole payment due under the Tranche A Note upon prepayment, if the option is fully exercised.
• Clarification of warrant terms ensures Oramed retains the original favorable exercise price of $0.01 per share for 6,500,000 shares, despite Scilex's reverse stock split.
• Oramed is entitled to receive dividends and distributions on the underlying shares as if the warrants were exercised, even if not yet exercised.

Negatives

• Oramed is restricted from exercising the Subject Warrants until Scilex forfeits its option or the agreement terminates.
• The repurchase is contingent on Scilex making timely payments and exercising the option.
• If the option is not fully exercised, Oramed's ability to exercise retained warrants may be limited by a 19.9% stockholder approval cap unless Scilex obtains further stockholder approval.
• The agreement includes a mutual release of claims related to the warrants, which could limit future legal recourse for past issues.

Risks

• Scilex may fail to make the required option payments ($1,500,000 total) or warrant repurchase payments ($27,000,000 total), leading to forfeiture of the option or termination of the agreement.
• If Scilex fails to exercise the option by the applicable dates, Oramed retains the warrants but may face limitations on their exercise due to stockholder approval caps.
• Scilex's ability to make payments is tied to its financial performance and potential equity financings, with 70% of certain proceeds earmarked for Oramed after Tranche A/B Note payments.
• Scilex covenants not to issue equity below $6.00 per share without Oramed's consent, which could limit Scilex's financing flexibility.

Future Outlook

The agreement outlines a clear path for Scilex to repurchase warrants from Oramed and potentially extend the maturity of a significant promissory note. This indicates a strategic move by Scilex to manage its capital structure and by Oramed to monetize its warrant holdings and secure the Tranche A Note. Future actions depend on Scilex's ability to meet payment deadlines and exercise the option.

Management Comments

• Nadav Kidron, President and CEO of Oramed Pharmaceuticals Inc., signed the 8-K report.
• Jaisim Shah, Chief Executive Officer and President of Scilex Holding Company, signed the Option Agreement.

Industry Context

This transaction reflects a common strategy in the biotechnology and pharmaceutical sectors where companies, often in early or mid-stages, use warrants and convertible notes as financing tools. The repurchase of warrants by Scilex suggests a move to simplify its capital structure and potentially reduce future dilution, while Oramed is monetizing its investment. The clarification regarding the warrant exercise price post-reverse split highlights the complexities of financial instruments in volatile biotech markets and the importance of precise disclosure.

Corporate Governance

Stakeholder Impact

• Shareholders (Oramed): Potential for cash inflow from warrant repurchase and option fee, and extended maturity for a significant note receivable, which could improve Oramed's liquidity and financial stability.
• Shareholders (Scilex): Potential reduction in future dilution by repurchasing warrants, but requires significant cash outlay. The extension of the Tranche A Note maturity provides more financial flexibility.
• Creditors (Scilex): The extension of the Tranche A Note maturity provides more time for repayment, potentially reducing immediate pressure on Scilex.

Next Steps

• Scilex to pay Oramed $750,000 by August 8, 2025, for the first option installment.
• Scilex to pay Oramed's counsel (Proskauer Rose LLP) outstanding legal fees by September 15, 2025.
• Scilex may repurchase 3,130,000 Subject Warrants for $13,000,000 by September 30, 2025.
• Scilex to pay Oramed $750,000 by December 16, 2025, for the second option installment.
• Scilex may repurchase 3,370,000 Subject Warrants for $14,000,000 by December 31, 2025.
• If all payments are made, the Tranche A Note maturity date will be extended to March 31, 2026.
• If the agreement terminates, Scilex will use commercially reasonable efforts to obtain stockholder approval for warrant issuance in excess of the Stockholder Approval Cap.

Key Dates

Recommendation

The agreement provides a structured path for Oramed to monetize its warrant holdings and secure the extension of a significant promissory note, which are positive developments for its financial position. However, the full realization of these benefits is contingent on Scilex's ability to meet its payment obligations and exercise the option. While the clarification of warrant terms is favorable, the overall impact is more about managing existing assets and liabilities rather than signaling new growth or significant operational changes. Given the contingent nature of the cash flows and the focus on existing financial instruments, a 'hold' recommendation is appropriate as investors should monitor the execution of the agreement and Scilex's financial performance.

Keywords

Oramed Pharmaceuticals, Scilex Holding Company, SEC Filing, 8-K, Warrant Repurchase, Promissory Note, Tranche A Note, Reverse Stock Split, Corporate Finance, Biotechnology, Pharmaceuticals, Investment, Corporate Governance